Ireland
--:--IST
Priya Life Science Clinical trial register
Trackers› Clinical trials› Changchun
Clinical trial register · China

Clinical Trials in Changchun, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19224 matching records held by the registry are in this view. Synced 11 Nov 2026, 03:17 UTC
19224
Studies in scope
all four open statuses
11811
Recruiting now
open to new participants
2030
Lead sponsors
across recruiting studies
Top sites
Beijing 7 Hefei 6 Guangzhou 6 Fuzhou 5 Bengbu 4
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca105 The First Hospital of Jilin University49 Hoffmann-La Roche31 Janssen Research & Development, LLC30 Eli Lilly and Company25 Novartis Pharmaceuticals21 Daiichi Sankyo18 Boehringer Ingelheim15 Sanofi12 Pfizer11 Jilin University8 Yi Yang8 GlaxoSmithKline7 Gilead Sciences7 AbbVie6 Merck Sharp & Dohme LLC5 Amgen5 BioNTech SE5 UCB Biopharma SRL5 Biotheus Inc.5 Ou Bai, MD/PHD4 Second Hospital of Jilin University4 Changchun GeneScience Pharmaceutical Co., Ltd.4 FengYan Jin4 Genmab4 Shanghai Jiao Tong University School of Medicine3 Takeda3 Peking Union Medical College Hospital3 MindRank AI Ltd3 Changchun Intellicrown Pharmaceutical Co. LTD3 Hutchmed3 Betta Pharmaceuticals Co., Ltd.3 Dizal Pharmaceuticals3 Northeast Normal University3 Tongji Hospital3 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.3 Acerta Pharma BV3 Abbisko Therapeutics Co, Ltd3 Yehui Tan3 Eisai Inc.3 China-Japan Union Hospital3 Novo Nordisk A/S3 Weill Medical College of Cornell University3 Beijing Tiantan Hospital3 Alexion Pharmaceuticals, Inc.3 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.3 Bristol-Myers Squibb3 Shanghai Pharmaceuticals Holding Co., Ltd2 Sun Yat-sen University2 Haisco Pharmaceutical Group Co., Ltd.2 Shanghai Jiaolian Drug Research and Development Co., Ltd2 Beijing InnoCare Pharma Tech Co., Ltd.2 Second Affiliated Hospital, Zhejiang University, School of Medicine2 Nanfang Hospital, Southern Medical University2 EMD Serono Research & Development Institute, Inc.2 Qilu Pharmaceutical Co., Ltd.2 CStone Pharmaceuticals2 Beijing Anzhen Hospital2 Cascade Pharmaceuticals, Inc2 Liu Hongfang2 Astellas Pharma Global Development, Inc.2 Shengjing Hospital2 Genentech, Inc.2 Southeast University, China2 Shanghai Pulmonary Hospital, Shanghai, China2 Shanghai Henlius Biotech2 Nanjing Leads Biolabs Co.,Ltd2 Sichuan Baili Pharmaceutical Co., Ltd.2 RemeGen Co., Ltd.2 Shanghai Junshi Bioscience Co., Ltd.2 Daehwa Pharmaceutical Co., Ltd.1 Ying Gao1 Beijing Children's Hospital1 Advenchen Laboratories Nanjing Ltd.1 MediLink Therapeutics (Suzhou) Co., Ltd.1 CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.1 Epizyme, Inc.1 Pierre Fabre Medicament1 Suzhou BlueHorse Therapeutics Co., Ltd.1 Xuanwu Hospital, Beijing1 ADC Therapeutics S.A.1 Shanghai HEP Pharmaceutical Co., Ltd.1 Jinling Hospital, China1 Jacobio Pharmaceuticals Co., Ltd.1 Karyopharm Therapeutics Inc1 Songling Zhang1 Shanghai Weihe Medical Laboratory Co., Ltd.1 Zai Lab (Shanghai) Co., Ltd.1 Peking University People's Hospital1 Jiangsu Alphamab Biopharmaceuticals Co., Ltd1 Viatris Innovation GmbH1 Aligos Therapeutics1 Suzhou Suncadia Biopharmaceuticals Co., Ltd.1 4D Molecular Therapeutics1 Foresight Therapeutics (Hefei) Co., Ltd.1 MSD R&D (China) Co., Ltd.1 Beeline Medicines Corporation1 Jianmin Pharmaceutical Group Co., LTD.1 Corxel Pharmaceuticals1 Ton-Bridge Medical Tech. Co., Ltd1 Epygenix1 OriCell Therapeutics Co., Ltd.1 First Hospital of China Medical University1 LEO Pharma1 Anthos Therapeutics, Inc.1 Dong Zhang1 Jilin Heart Hospital1 Lifetech Scientific (Shenzhen) Co., Ltd.1 DualityBio Inc.1 Wuhan Humanwell Innovative Drug Research and Development Center Limited Company1 SPH Sine Pharmaceutical Laboratories Co., Ltd.1 Gracell Biotechnologies (Shanghai) Co., Ltd.1 Chunyan Ma1 Elpiscience (Suzhou) Biopharma, Ltd.1 Shanghai Jiatan Pharmatech Co., Ltd1 Chinese SLE Treatment And Research Group1 Chongqing Jinsaixing Medical Technology Co., Ltd1 Shanghai University of Traditional Chinese Medicine1 Bayer1 Nanjing IASO Biotechnology Co., Ltd.1 Excyte Biopharma Ltd1 Stryker Neurovascular1 tongweihua1 Sinocelltech Ltd.1 Dizal (Jiangsu) Pharmaceutical Co., Ltd.1 Xuanzhu Biopharmaceutical Co., Ltd.1 Shanghai Zhimeng Biopharma, Inc.1 City University of Hong Kong1 jiuwei cui1 manxiaxia1 Geneplus-Beijing Co. Ltd.1 Chengdu Suncadia Medicine Co., Ltd.1 Celgene1 InnoCare Pharma Inc.1 Suzhou Siran Biotechnology Co.,Ltd.1 Beijing Hospital1 Parr Biotechnology (Hebei) Co., Ltd.1 European Myeloma Network B.V.1 Pentax Medical1 Xynomic Pharmaceuticals, Inc.1 Astellas (Beijing) Pharmaceutical R&D Co., Ltd.1 Peking University Hospital of Stomatology1 Tang-Du Hospital1 oubai, MD/PhD1 Eye & ENT Hospital of Fudan University1 The Cleveland Clinic1 Hangzhou Endonom Medtech Co., Ltd.1 Shanghai QuietD Biotechnology Co., Ltd.1 Hangzhou Sumgen Biotech Co., Ltd.1 Jiangsu Jingze Biopharmaceutical Co., Ltd.1 Institute of Hematology & Blood Diseases Hospital, China1 Smith & Nephew, Inc.1 Shanghai Simnova Biotechnology Co.,Ltd.1 Jiangsu Simcere Pharmaceutical Co., Ltd.1 Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany1 Alpine Immune Sciences Inc, A Subsidiary of Vertex1 Chinese PLA General Hospital1 Laekna Limited1 Ausper Biopharma Co., Ltd.1 Candid Therapeutics1 Jazz Pharmaceuticals1 Tasly Pharmaceutical Group Co., Ltd1 Di Wu1 Kexiang Liu, MD1 Healthgen Biotechnology Corp.1 Beijing Continent Pharmaceutical Co, Ltd.1 Huahui Health1 Ruijin Hospital1 Ascentage Pharma Group Inc.1 LeonaBio1 Shanghai Best-Link Bioscience, LLC1 OBI Pharma, Inc1 Children's Hospital of Soochow University1 Allist Pharmaceuticals, Inc.1 Newish Biotech (Wuxi) Co., Ltd.1 Klus Pharma Inc.1 Vertex Pharmaceuticals Incorporated1 Alnylam Pharmaceuticals1 Jiangsu Hansoh Pharmaceutical Co., Ltd.1 Sinotau Pharmaceutical Group1 Shenzhen Kexing Pharmaceutical Co., Ltd.1 Ascentawits Pharmaceuticals, Ltd1 AriBio Co., Ltd.1 Chinese Academy of Medical Sciences, Fuwai Hospital1 Tianjin Medical University Cancer Institute and Hospital1 Taiho Oncology, Inc.1 ArriVent BioPharma, Inc.1 Fudan University1 Xiamen Amoytop Biotech Co., Ltd.1 Zhejiang Doer Biologics Co., Ltd.1 Mirum Pharmaceuticals, Inc.1 Innovent Biologics (Suzhou) Co. Ltd.1 Chipscreen Biosciences, Ltd.1 Mundipharma (China) Pharmaceutical Co. Ltd1 Shouchun Wang, MD, PhD1 argenx1 B. Braun Medical International Trading Company Ltd.1 Harbin Medical University1 Zan Wang1 Ipsen1 Clear sponsor filter
Target enrolment
to

Trials with a site in Changchun

1 of 19224 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
DualityBio Inc.
Phase 1/2
1,000
Zhengzhou, Changsha, Nanjing, Wuxi, Changchun, Shenyang, Shanghai, Chengdu
2023-08-17
Rows per page Showing 1–1 of 1
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 11 November 2026. https://priyalifescience.com/clinical-trials-china/city/changchun

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,224 studies in total at the last sync on 11 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1 of those studies with a site in Changchun that also match the filters currently applied.

How many clinical trials are recruiting in Changchun?

1 of the 1 studies on this page are recruiting new participants as of the 11 Nov 2026, 03:17 UTC sync. A further 0 have not yet opened recruitment, 0 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Changchun), 1 studies
PhaseStudiesRecruitingShare
Phase 1/211100%

Most active sponsors

Lead sponsors with the most studies (Changchun)
Lead sponsorStudiesRecruiting
DualityBio Inc.11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.